IMPROVE will use Patient Generated Health Data (PGHD) gathered via m-health and e-health technologies to gain improved insights into the real-life behavior of, and challenges faced by, patients of all ages with complex, chronic diseases and comorbidities. Already today, a wealth of patient and citizen information is available, but fragmented, and therefore not coming to its full utility and value. These personal data will complement and improve existing approaches for Patient-Centered Outcome Measures beyond those currently available in state-of-the-art platforms. The IMPROVE platform that the consortium will build will enable the smart use of patient input and patient generated evidence to 1) advance the role of patient preference and patient experience in the context of treatment selection, 2) improve medical device design based on patient preferences and experiences, and 3) facilitate faster market entry of patient-centric and cost-effective advanced integrated care solutions. Improved clinical adoption of Value Based Health Care, and enhanced return on research and innovation investments will be demonstrated in different care settings across the EU, for 10 use cases in at least 5 different disease areas (e.g., ophthalmology, oncology, cardiovascular disease, chronic inflammation, and neurology). The use cases will be conducted using a large variety of implementation strategies, building on a design thinking approach, to optimally test the innovative framework of data gathering and translation into controlled change and action. In addition, a significant contribution from implementation science is planned to reach out to all stakeholders that are relevant for this initiative and maximise the impact to IMPROVE healthcare provision.

Despite emotions being a driver of political choices, building democratically meaningful emotional narratives in politics remains an uncharted territory. Hence the main venture of ENCODE is to decode the meanings of emotions and encode them to policy-making strategies aiming for a positive emotional turn, breaking the cycle of depolarisation. To meet this ambitious goal, ENCODE builds its conceptual frameworks arising from a novel concept of affective pluralisation, as opposed to affective polarisation. This term serves to frame empirical research carried out in 6 geographically diverse European countries, representing both EU member states and candidates. This study will span desk research, sentiment analysis, biometric research, in-depth interviews, experiments and panel survey. Such triangulation of research techniques ensures the accuracy and validity of the findings. These are further encoded into main outputs: catalogue of best practice to tackle disinformation in social media, emotional gap maps, validated survey questions and democratic resilience heatmaps. These outputs are not expected only to enhance current scientific framework, but also are planned to underpin the future emotional narratives co-designed by diverse groups of citizens in innovations labs and further validated by Delphi expert panels and vignette experiments. This bottom-up approach anchored in citizen science ensures that policy-making strategy are in first place created by citizens and only in the next step discussed by expert teams who will elaborate policy-making strategies, the roadmap for their implementation, alongside future foresight scenarios which will be disseminated widely across EU and EU wide community of 1000+ members. This strategy creates emotional bonds between ordinary citizens, increases trust in governance and supports better informed political decision-making and communication.

Deep vein thrombosis (DVT) is the formation of a blood clot within the deep veins, most commonly those of the lower limbs, causing obstruction of blood flow. In 50% of people with DVT, the clot eventually breaks off and travels to the lung to cause pulmonary embolism. Clinical assessment of DVT is notoriously unreliable because up to 2/3 of DVT episodes are clinically silent and patients are symptom free even when pulmonary embolism has developed. Early diagnosis of DVT is crucial and despite the progress made in ultrasound imaging and plethysmography techniques, there is a need for new methods to enable continuous monitoring DVT diagnosis at the point of care. ThrombUS+ brings together an interdisciplinary team of industrial, technology, regulatory, social science and clinical trial experts to develop a novel wearable diagnostic device for point-of-care, operator free, continuous monitoring in patients with high DVT risk. The device will combine autonomous, AI driven DVT detection based on a novel wearable ultrasound hardware, impedance plethysmography and light reflection rheography for immediate detection of blood clot formation in the lower limb. Activity and other physiological measurements will be used to provide a continuous assessment of DVT risk and support DVT prevention via serious gaming. The aggregated data will drive an intelligence decision support unit that will provide accurate monitoring and alerts. Extended reality will be used to guide experts to design exercises and patients to use the device optimally. ThrombUS+ is intended for use by postoperative patients in the ward, during long surgical operations, cancer patients or otherwise bedridden patients at home or in care units, and women during pregnancy and postpartum. ThrombUS+ will use big data sets for AI training collected in the project via 3 large scale clinical studies and will validate the outcome in the clinical setting via 1 early feasibility study and 1 multi-center clinical trial.

The GRACE integrated solution aims to transform the healthcare ecosystem by providing essential knowledge and innovative public-private partnership for (1) reorganizing healthcare services (2) with embedded innovative technologies and tools, helping identifying and overcoming barriers and gaps that are now hindering CVD management, ensuring a seamless continuum of care and optimized care pathways. Our vision is that introducing effective health technology and interventions is economically, societally and environmentally sustainable if and only accompanied by a substantial healthcare service re-organization. Accordingly, GRACE will focus on an end-to-end clinical pathway CVD, considering an holistic view of the patient and optimizing healthcare services leveraging on advanced technological solutions. GRACE intervention will be multifold aiming at: (1) guiding strategic policies, (2) drive market innovation, and (3) foster effective healthcare delivery practices in CVD, generating value for patients, healthcare workers and system. GRACE will enable early and personalized interventions, fostering coordination of multidiscipline healthcare teams, triggering more intense and person-specific management using innovative technologies, AI and digital solutions for early detection of red flags, promoting patient empowerment, while comprehensively containing CVD risk factors and burden. A multidisciplinary consortium of experienced and competitive partners will implement this vision and implement the proposed solution in a novel multidiscipline manner.

The Gravitate-Health mission is to equip and empower citizens with digital information tools that make them confident, active, and responsive in their patient journey, specifically encouraging safe use of medicines for better health outcomes and quality of life. It is our vision that engagement of citizens in their own health can only be achieved with access to actionable, understandable, relevant, reliable and evidence-based information that meets their specific needs, health context, and literacy level. This project's ambition is to provide a key piece to advance this vision: the Gravitate Lens (G-lens), which focuses (but does not conceal or filter) approved electronic product information (ePI) content, and offers a route for patients to access trustworthy, up-to-date information that better meet their individual needs. Gravitate-Health is an integrated digital health information project. The principle objective is to demonstrate how use of an integrated, digital, user-centric health information solution with two-way communication could enable tangible improvements in availability and understanding of health information from a set of trusted sources, starting with regulator-approved medicinal product information (e.g. package leaflet content) and EHR-IPS (International Patient Summary). The secondary objectives are to demonstrate that the improved availability and understanding of health information from trusted sources translate to higher levels of adherence to treatment, safer use of medication (Pharmacovigilance), better health outcomes and quality of life, and to develop new and deeper insights into how use of available health information can be optimized to act as effective risk minimization measures. The project allows for efficient and timely development of the G-lens, provides testing grounds for new services and an evaluation framework to test the efficiency, efficacy and safety of Gravitate-Health services. Our main outputs will be an open source digital platform supporting G-lens functionally, demonstrated in a number of testing scenarios, and a White Paper with recommendations on realistic strategies to strengthen access, understanding and future use of digital services like ePIs as a tool for Risk Minimization. The Gravitate-Health is a public – private partnership with 45 members from Europe and the US, co-led by University of Oslo (coordinator) and Pfizer (industry lead), funded by the Innovative Medicines Initiative (IMI) – a joint undertaking of the European Commission, the European Federation of Pharmaceutical Industries and Associations (EFPIA), IMI Associated Partners.